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Mantle cell lymphoma (MCL) comprises 3–10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas
represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response
rates are typically achieved in these patients with current ﬁrst-line chemoimmunotherapy. However, most patients will eventually
relapse and become chemorefractory with poor outcome. Alternative chemoimmunotherapy regimens are often used as salvage
strategy and stem cell transplant remains an option for selected patients. However, novel approaches are urgently needed for
patients no longer responding to conventional chemotherapy. Lenalidomide is an immunomodulatory drug with activity in
multiple myeloma, myelodisplastic syndrome and chronic lymphoproliferative disorders. In phase II studies of indolent NHL
and MCL lenalidomide has shown activity with encouraging response rates, both as a single agent and in combination with other
drugs. Some of these responses may be durable. Optimal dose of lenalidomide has not been deﬁned yet. The role of lenalidomide
in the therapeutic armamentarium of patients with indolent NHL or MCL will be discussed in the present paper.
1.Introduction
Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous
group of lymphoid malignancies. The annual incidence of
NHL in the United States is estimated to be 4.5% of all
cancers, and they account for 3% of annual cancer-related
deaths [1]. From a clinical and therapeutic standpoint, these
neoplasiasaresubdividedintoaggressiveandindolentforms.
Indolent lymphomas represent approximately 30% of all
NHLs. Prognosis is correlated with the stage of the disease
at the time of diagnosis, as well as to the international prog-
nostic index (IPI) or other IPI-derived scores [2–5]. The
current therapeutic approach for indolent NHL is based
on the use of chemoimmunotherapy. Intensive treatments
such as high-dose chemotherapy with autologous stem cell
transplantation (ASCT) are typically reserved for relapsing
patients whose disease is still chemosensitive [1].
Mantle cell lymphoma (MCL) comprises approximately
3 to 10% of NHL. It is a heterogeneous clinical entity with
fourrecognizedmorphologicvariants(i.e.,classical,blastoid,
pleomorphic and small cell, marginal zone-like). The small
cell variant tends to be an indolent lymphoma, whereas both
the blastoid and pleomorphic variants are associated with a
clinical aggressive course.
However, the majority (80%) of MCLs show intermedi-
ate characteristics. Thus, the median survival of the majority
ofpatientsisintherangeof3to5years,andveryfewpatients
are cured [2].
MCL patients typically respond well to initial treatment
with an overall response rate of approximately 90%. The
addition of rituximab to conventional chemotherapy has
even improved both quality and durability of responses
either in newly diagnosed or relapsed disease [6, 7].
However, most patients will eventually relapse, with
shorter and shorter disease-free intervals, and will require
multiple diﬀerent therapeutic interventions during the
course of their disease [8, 9]. For this reason, there is a need
for new eﬀective agents with novel mechanisms of action to
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Table 2: Ongoing lenalidomide (L) monotherapy trials.
Name Phase Age Histology Drugs Status
NCT00875667 II >18ys Relapsed or refractory MCL L Ongoing and recruiting
NCT00737529 II >18ys Relapsed or refractory MCL L Ongoing and recruiting
NCT00179673 II >18ys Relapsed or refractory indolent NHL L Terminated
L: lenalidomide.
2. Rationale for and Development of
Lenalidomide in Lymphoproliferative
Disorders
Lenalidomide is an immunomodulatory drug (IMiD),
derived from thalidomide, with increased potency and fewer
side eﬀects compared to its parent molecule. This agent has
shown impressive clinical activity in patients with multiple
myeloma (MM) [15]a n dh a sp r o v e ne ﬀective in chronic
lymphocyticleukemia(CLL)[16]andT-celllymphoma[17].
Preclinical models and preliminary clinical data also indicate
signiﬁcant antitumor activity of lenalidomide in B-cell
malignancies [18, 19].
The mechanism of action of lenalidomide includes both
immunomodulatory and nonimmunomodulatory eﬀects
[20–24]. It inhibits the production of proinﬂammatory cyto-
kines (TNF-α, IL-1, IL-6, and IL-12) and enhances that of
anti-inﬂammatory cytokine (IL-10) resulting in an increase
of the tumor-cell apoptosis [20–22]. Lenalidomide also
induces tyrosine phosphorylation of CD28, providing a cos-
timulatory signal to T-cell activation by antigen-presenting
cells via the B7 pathway [20–22]. IMiDs can decrease the
expression of the angiogenic factors VEGF and IL-6 leading
to a reduction of growth and survival of tumor cells [20–25].
Lenalidomide increases the number and Fc-γ receptor-med-
iated cytotoxicity of NK cells with an as-yet unclear mecha-
nism of action [20]. Importantly, lenalidomide has also
shown direct antiproliferative activity, in the absence of
immune eﬀectors, by decreasing erk1/2 and Akt2 and by
inducing G0-G1 cell cycle arrest through inhibition of CDK2
activity [20–23]. Finally, in MM, lenalidomide has been
shown in vitro to alter the microenvironment by downreg-
ulating cell surface adhesion molecules such as ICAM-1,
VCAM-1, and E -selectin and inhibiting the adhesion of MM
cell lines to the bone marrow stromal cells [20, 21].
3. Lenalidomide Monotherapy in
Relapsed/Refractory Indolent and
Mantle Cell Lymphoma
Oral lenalidomide monotherapy produces durable responses
in patients with NHL with a manageable toxicity proﬁle
(Table 1). In a pilot study of relapsed/refractory aggressive
NHL, also including 15 and 5 stage III follicular lymphoma
(FL) patients, lenalidomide induced an objective response
rate of 35% with 12% complete responses/unconﬁrmed
complete responses [10]. Patients enrolled in the study had
received a median of 4 prior therapies. Fifty eight percent
of patients were rituximab refractory. The most frequent G3
toxicity was neutropenia. A dose reduction was necessary in
18 (37%) patients (9 patients to 20mg, 5 patients to 15mg,
3 patients to 10mg, and 1 patient to a 5mg daily dose). Eight
patients (16%) discontinued treatment because of adverse
events. In a second trial [11]o fh e a v i l yp r e t r e a t e di n d o l e n t
NHL patients (median number of prior lines 3 (1–17)),
single-agent lenalidomide resulted in an ORR of 23% (27%
in follicular and 22% in small lymphocytic lymphoma).
Median duration of response was not reached with a
followup of 15 to 28 months. Median PFS for the whole
group was 4.4 months (95% CI, 2.5–10.4). The most fre-
quentG3toxicitieswerehematological(neutropenia,throm-
bocytopenia, and anemia). Seventeen patients (40%) had a
dose reduction (6 patients to 20mg, 3 patients to 15mg, 6
patients to 10mg, and 2 patients to a 5mg daily dose). Eight
patients (19%) discontinued treatment because of adverse
events, and 1 died on treatment due to sepsis. In another
study of relapsed/refractory MCL, lenalidomide showed an
overall response rate (ORR) of 43%. Twenty six percent of
the patients had received stem cell transplantation and 32%
had been exposed to bortezomib. ORR in these two groups
was 53% and 57%, respectively. The most common grade 3
or 4 adverse event was neutropenia (43%) [12]. In a smaller
study including 15 patients, 58% of whom being rituximab
refractory, objective responses were achieved in 53% of cases
with a 20% complete remission (CR) rate [13, 26]. Eight
patients (53%) had a dose reduction, but only 1 patient
discontinued treatment. Finally, Witzig et al. [14]t r e a t e d
217 aggressive relapsed/refractory NHLs, including 26% of
patients with MCL. Median number of prior chemotherapy
lines was 3 (1–13). MCL patients showed an ORR of 42%
with a median progression-free survival (PFS) not reached.
Fifty three (53%) of patients required dose reduction (37
patients to 20mg, 11 patients to 15mg, 9 patients to 10mg,
and 10 patients to a 5mg daily dose), and 23% discontinued
lenalidomide. Most G3-G4 toxicities recorded were hema-
tological (41% neutropenia, 19% thrombocytopenia, and
9.2% anemia). Ongoing trials of single-agent lenalidomide
in refractory indolent NHL and MCL are summarized in
Table 2. While in untreated patients a lenalidomide daily
dose of 25mg may be appropriate (see Table 1), in patients
with relapsed or refractory disease, particularly if they are
elderly and/or suﬀering from other comorbidities, a lower
dose (15 to 20mg) appears to be a wiser choice. Of note,
because of the proliferation of phase II studies with diﬀerent
starting doses, and the dose-escalating design of several
ongoing lenalidomide trials, a dose that is considered “rea-
sonable” may not necessarily be the optimal one.4 Advances in Hematology
Table 3: Lenalidomide containing regimens in relapsed/refractory indolent and mantle cell lymphoma.
Author Year Phase Histology n Age (range) Previous CT Combination ORR (%) CR (%)
Wang et al. [27] 2007 I/II MCL 15 73 (62–84) 2 (1–7) RL 83∗ 17∗
Dutia et al. [28] 2009 II Indolent NHL 15 60 (50–91) 4 (1–11) RL 83.3 41
Zaja et al. [29] 2011 II MCL 33 68 (51–80) 3 (2–7) LD 52 24
∗: data from patients enrolled in lenalidomide 20mg/daily arm. No response was obtained for lower dosage.
CT: chemotherapy; ORR: overall response rate; CR: complete response; RL: rituximab and lenalidomide; LD: lenalidomide and dexamethasone.
Table 4: Ongoing lenalidomide-based regime trials.
Name Phase Age Histology Drugs Status
NCT01419795 II >18ys Relapsed or refractory NHL after allo-SCT RL Ongoing and recruiting
NCT00238238 II >18ys Relapsed follicular NHL RL Ongoing and recruiting
NCT00633594 I/II >18ys Relapsed or refractory MCL RVL Ongoing and recruiting
NCT00553644 (27) II >18ys Relapsed or refractory MCL LV Ongoing and recruiting
RL: rituximab, lenalidomide; RVL: rituximab, bortezomib, lenalidomide; LV: lenalidomide, bortezomib.
4. Lenalidomide in Combination for
Relapsed/Refractory Indolent andMCL
The Fc portion of rituximab mediates ADCC. Lenalidomide
increases Fc-γ receptors on NK cell surface enhancing
rituximab-mediated ADCC. Many trials have therefore eval-
uated the two drugs in combination (Tables 3 and 4). In a
phase I/II study [27] of rituximab (375mg/m2 weekly for
4 doses) and escalating doses of lenalidomide (from 10 to
25mg daily on days 1–21 of 28-day cycles for a total of 6
cycles) in relapsed or refractory MCL, no responses were
observed in the 10mg and 15mg groups, while patients
receiving 20mg daily achieved an ORR of 83%, including
17%ofcompleteresponses.Atthedoseof25mg,aG3hyper-
calcemia and a lethal neutropenic fever were observed. The
recommended lenalidomide daily dose to be used in com-
bination with rituximab in phase II trials was therefore
established to be 20mg. Dutia et al. [28] tested rituximab
(375mg/m2 weekly for 4 doses plus 4 doses if no CR was
reached) and lenalidomide (20mg daily on days 1–21 of 28-
day cycles) in heavily pretreated patients with indolent NHL.
T r e a t m e n tp r o v e da c t i v ea n dw e l lt o l e r a t e d( n od o s er e d u c -
tions nor discontinuations were reported), particularly in
patients with rituximab-refractory FL (response rate of
55%). In a recent phase II study that enrolled patients with
MCL and either relapsed/refractory disease or ineligibility to
intensive treatment, lenalidomide 25mg daily for days 1–21
plus dexamethasone (40mg on days 1, 8, 15, and 22) were
given as postinduction consolidation therapy for 3 (patients
in CR) or up to 12 (patients in partial remission/stable dis-
ease—PR/SD) cycles. Treatment was discontinued at CR or
unacceptabletoxicity.Thestudyenrolled33patients.Median
number of prior treatments was 3 (2–7). After a median
followup of 16 months, median PFS and OS were 12 and
20 months, respectively, with median response duration of
18 months. Treatment was well tolerated, the most frequent
toxicitybeingneutropenia(grade3in25%,grade4in28%of
patients), leading to treatment interruption in two patients.
Overall 9 serious adverse events were recorded, including
one therapy-related fatal acute respiratory insuﬃciency [29].
Phase II trials are underway to test diﬀerent combinations,
notably including bortezomib plus lenalidomide [30].
5. Lenalidomide in Combination for Untreated
Indolent andMantle CellLymphoma
The combination of rituximab and lenalidomide has also
been tested in previously untreated patients with indolent
N H La n dM C L( T a b l e s5 and 6). In an ongoing study of 30
patients with advanced-stage indolent NHL and indication
for treatment, [31] rituximab (375mg/m2 on day 1 of each
28-daycycle)andlenalidomide(20mg/dayondays1–21)for
6 cycles produced an ORR of 86% and an overall response
rate (CRR) of 79%. Only 2 patients required treatment dis-
continuation due to toxicities leading the investigators to
expand the originally planned accrual and include a total
of 110 patients. In a study of 75 patients with indolent
NHL [32], the same combination induced responses in 90%
of patients with a 66% CRR. Only 5 patients discontinued
treatment within the ﬁrst two cycles due to toxicity. In a
recent phase I trial [33], escalating doses of lenalidomide
(from 5 to 25mg once daily on days 1–14) were associated
to R-CHOP21 (rituximab 375mg/m2, cyclophosphamide
750mg/m2,doxorubicin50mg/m2,vincristine1.4mg/m2 on
day 1, and prednisone 100mg/m2 days 1–5 every 21 days) for
6 cycles in untreated B-cell lymphomas. Lenalidomide 25mg
wasestablishedastherecommendeddose.Themostfrequent
toxicity was hematological (grade 3-4 neutropenia in 59%
of patients), 6 patients experienced cycle delay, and 5 dis-
continued treatment, but no toxic death occurred.
Strategies to build on the use of lenalidomide as a single
agent appear the avenue to pursue. The role of dexametha-
sone is marginal, if any. On the contrary, the association
of lenalidomide and rituximab appears to be feasible and
shows encouraging activity in untreated and previously
treated patients with indolent and MCL. The combination
of lenalidomide with chemoimmunotherapy regimens such
as R-CHOP is attracting, but both its feasibility and eﬃ-
cacy need to be tested in further prospective trials. Finally,Advances in Hematology 5
Table 5: Lenalidomide containing regimens in untreated indolent and mantle cell lymphoma.
Author Year Phase Histology n Age (range) Combination ORR (%) CR (%)
Fowler et al. [31] 2010 II Indolent NHL 30 56 (36–77) RL 86 79
Samaniego et al. [32] 2011 II Indolent NHL 75 57 (35–84) RL 90 66
Tilly et al. [33] 2011 I NHL 27 NR RL-CHOP 96 74
ORR: overall response rate; CR: complete response; NR: not reported; RL: rituximab and lenalidomide; RL-CHOP: rituximab, lenalidomide, cyclophos-
phamide, doxorubicin, vincristine, prednisone.
Table 6: Ongoing lenalidomide-based regime trials.
Name Phase Age Histology Drugs Status
NCT01415752 II >60 ys Untreated MCL RBV+ RL Ongoing and recruiting
NCT01316523 II >18ys Untreated indolent NHL RL Ongoing and recruiting
NCT00695786 II >18ys Untreated indolent NHL RL Ongoing and recruiting
FIL R2-B II >18ys Untreated indolent NHL RBL Ongoing and recruiting
RBV: rituximab, bendamustine, bortezomib; RL: rituximab, lenalidomide; RBL: rituximab, bendamustine, lenalidomide.
Table 7: Ongoing lenalidomide-maintenance trials.
Name Phase Age Histology Drugs Status
NCT01035463 I/II >19ys Relapsed or refractory NHL R-BEAM + ASCT + mL Ongoing and recruiting
NCT01035463 I/II >18ys Relapsed or refractory NHL R-BEAM + ASCT + mL Ongoing and recruiting
NCT01254578 I >18ys High-risk hematologic cancers after Allo-SCT mL Ongoing and recruiting
NCT01045928 I/II >18ys NHL R + mL Ongoing not recruiting
NCT01021423 III >18ys Untreated MCL FCR or R-CHOP + mL Ongoing not recruiting
IIL MCL0208 III 18–60ys Untreated MCL R-BEAM + ASCT + mL Ongoing and recruiting
R-BEAM: rituximab, BCNU, etoposide, ara-C, melphalan; ASCT: autologous stem cell transplantation; mL: lenalidomide maintenance; R: rituximab; FCR:
ﬂudarabine, cyclophosphamide; rituximab; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
the exploration of lenalidomide in other chemotherapy-free






for patients with MCL. One agent that proved successful
in this context is rituximab [34]. Twenty-two untreated
MCLs not candidate for autologous stem cell transplantation
were treated with a maximum of 6 cycles repeated every
28 days of modiﬁed R-hyper-CVAD (rituximab, hyperfrac-
tionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone)followedbyrituximabmaintenance(weekly
doses every 6 months for a total of 4 courses). ORR and CRR
were impressive (77% and 64%, resp.). In a recently pre-
sented multicenter phase III trial [35], 560 untreated elderly
(>60ys) patients not eligible for high-dose therapy were ran-
domized to receive R-CHOP or rituximab, ﬂudarabine, and
cyclophosphamide followed by a maintenance phase with
either rituximab or interferon-alfa. Rituximab maintenance
doubled the remission duration compared to IFN (57%
versus 26% at 4 years, resp., P = 0.0109). Not surprisingly,
hematologic grade 3-4 toxicity was higher in the IFN arm.
Overall survival did not diﬀer between both maintenance
arms (P = 0.17). Another randomized phase III trial eval-
uated the eﬃcacy of lenalidomide versus placebo as mainte-
nance therapy after ﬁrst-line induction in patients with MCL
not candidates for intensive treatment. Lenalidomide was
given orally at the dose of 15mg daily on days 1–21 every 28
days for 2 years, up to either disease progression or unac-
ceptable toxicity, whichever occurred ﬁrst. Only 9 patients
(4 in CR and 5 in PR) were randomized (4 in the lenalido-
mide maintenance arm and 5 in the placebo). Two patients
discontinued treatment due to toxicity and disease pro-
gression in the treatment and placebo arm, respectively.
The study was prematurely terminated, and most analyses
were not performed. A phase I/II Scandinavian trial [36]i s
ongoing in which lenalidomide is combined with rituximab
(375mg/m2 on day 1) and bendamustine (90mg/m2 on days
1-2) as induction in untreated elderly (>65 years) MCL
patients. Six 28-day induction cycles are followed by seven
28-day cycles of maintenance lenalidomide (25mg daily
on days 1–21). Recently, Ahmadi et al. [37]i n v e s t i g a t e d
the safety and eﬃcacy of lenalidomide and rituximab in
relapsed/refractory indolent or mantle cell lymphoma. Forty
ﬁve sequential patients received two 28-day treatment cycles
of lenalidomide 10mg every day and four weekly doses of
rituximab 375mg/m2 in cycle 3 with (cohort 1) or without6 Advances in Hematology
(cohort 2) weekly dexamethasone. In stable and responding
patients, lenalidomide and dexamethasone (cohort 1) or
lenalidomide alone (cohort 2) was continued until disease
progression or unacceptable toxicity (median number of
prior therapies was 3 (1–7)). Thirty ﬁve patients were eval-
uable for response. At a median followup of 11.8 months,
PFS was 73% (95% CI: 53–86%), and ORR was 60% (12CR;
9PR).ORRdidnotdiﬀerbetweencohort1andcohort2,P =
0.5. Half of the patients temporarily suspended treatment,
while 2 discontinued therapy. Several other trials of lenalido-
mide maintenance in patients with untreated or relapsed/
refractory NHL are underway (Table 7).
7. Conclusions
Lenalidomide is an immunomodulatory agent with remark-
able activity in a variety of lymphoproliferative disorders. Its
value is well established in multiple myeloma, and increasing
evidence supports its role in the management of CLL
patients. Phase II data are also delineating a role for lenalido-
mide in NHL, including MCL and indolent NHLs. Response
rates are encouraging with response lasting 6.2 to 16.5
months in relapsed NHL when used alone. The drug is gen-
erally tolerated with hematological adverse events being the
most common toxicity, and no unexpected toxicities in
numericallylimitedtrialstheoptimaldoseoflenalidomidein
maintenance or in combination with other agents remains to
be deﬁned. Single-agent lenalidomide 25mg may be appro-
priate in young untreated patients, while a lower dose (15 to
20mg) should be considered in relapsed/refractory elderly
patients. The route is traced out, but informative, random-
ized phase III trials with careful study design and adequate
patient numbers will be necessary to deﬁne the role of
lenalidomide in the therapeutic armamentarium of patients
with NHL.
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